Decision-making process for introduction of maternal vaccines in Kenya, 2017-2018.
Decision-making
Maternal vaccines
Policy formulation
Policy implementation
Journal
Implementation science : IS
ISSN: 1748-5908
Titre abrégé: Implement Sci
Pays: England
ID NLM: 101258411
Informations de publication
Date de publication:
12 04 2021
12 04 2021
Historique:
received:
06
04
2020
accepted:
19
03
2021
entrez:
13
4
2021
pubmed:
14
4
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Maternal immunization is a key strategy for reducing morbidity and mortality associated with infectious diseases in mothers and their newborns. Recent developments in the science and safety of maternal vaccinations have made possible development of new maternal vaccines ready for introduction in low- and middle-income countries. Decisions at the policy level remain the entry point for maternal immunization programs. We describe the policy and decision-making process in Kenya for the introduction of new vaccines, with particular emphasis on maternal vaccines, and identify opportunities to improve vaccine policy formulation and implementation process. We conducted 29 formal interviews with government officials and policy makers, including high-level officials at the Kenya National Immunization Technical Advisory Group, and Ministry of Health officials at national and county levels. All interviews were recorded and transcribed. We analyzed the qualitative data using NVivo 11.0 software. All key informants understood the vaccine policy formulation and implementation processes, although national officials appeared more informed compared to county officials. County officials reported feeling left out of policy development. The recent health system decentralization had both positive and negative impacts on the policy process; however, the negative impacts outweighed the positive impacts. Other factors outside vaccine policy environment such as rumours, sociocultural practices, and anti-vaccine campaigns influenced the policy development and implementation process. Public policy development process is complex and multifaceted by its nature. As Kenya prepares for introduction of other maternal vaccines, it is important that the identified policy gaps and challenges are addressed.
Sections du résumé
BACKGROUND
Maternal immunization is a key strategy for reducing morbidity and mortality associated with infectious diseases in mothers and their newborns. Recent developments in the science and safety of maternal vaccinations have made possible development of new maternal vaccines ready for introduction in low- and middle-income countries. Decisions at the policy level remain the entry point for maternal immunization programs. We describe the policy and decision-making process in Kenya for the introduction of new vaccines, with particular emphasis on maternal vaccines, and identify opportunities to improve vaccine policy formulation and implementation process.
METHODS
We conducted 29 formal interviews with government officials and policy makers, including high-level officials at the Kenya National Immunization Technical Advisory Group, and Ministry of Health officials at national and county levels. All interviews were recorded and transcribed. We analyzed the qualitative data using NVivo 11.0 software.
RESULTS
All key informants understood the vaccine policy formulation and implementation processes, although national officials appeared more informed compared to county officials. County officials reported feeling left out of policy development. The recent health system decentralization had both positive and negative impacts on the policy process; however, the negative impacts outweighed the positive impacts. Other factors outside vaccine policy environment such as rumours, sociocultural practices, and anti-vaccine campaigns influenced the policy development and implementation process.
CONCLUSIONS
Public policy development process is complex and multifaceted by its nature. As Kenya prepares for introduction of other maternal vaccines, it is important that the identified policy gaps and challenges are addressed.
Identifiants
pubmed: 33845842
doi: 10.1186/s13012-021-01101-7
pii: 10.1186/s13012-021-01101-7
pmc: PMC8042952
doi:
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
39Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Références
BMC Public Health. 2014 Aug 16;14:855
pubmed: 25128911
Wkly Epidemiol Rec. 2006 May 19;81(20):198-208
pubmed: 16710950
Int J Health Policy Manag. 2017 Apr 08;6(12):707-720
pubmed: 29172378
Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76
pubmed: 23210147
Epidemiol Rev. 1999;21(1):24-42
pubmed: 10520471
Clin Infect Dis. 2020 May 23;70(11):2306-2313
pubmed: 31544211
PLoS One. 2014 Jun 23;9(6):e98615
pubmed: 24955962
Hum Vaccin Immunother. 2020 Oct 2;16(10):2429-2437
pubmed: 32208952
Lancet Infect Dis. 2008 Jan;8(1):44-52
pubmed: 18156088
Lancet. 2011 Aug 6;378(9790):526-35
pubmed: 21664679
Vaccine. 2015 Nov 25;33(47):6376-9
pubmed: 26319068
J Health Popul Nutr. 2013 Jun;31(2):211-7
pubmed: 23930339
Influenza Other Respir Viruses. 2016 Jul;10(4):254-67
pubmed: 26842617
PLoS One. 2011 Jan 18;6(1):e16085
pubmed: 21267459
Clin Infect Dis. 2020 Jul 29;71(Supplement_2):S172-S178
pubmed: 32725235
Hum Vaccin Immunother. 2016 Apr 2;12(4):857-65
pubmed: 26552807
Glob Public Health. 2013;8(10):1138-50
pubmed: 24294986
Int J Equity Health. 2017 Sep 15;16(1):169
pubmed: 28911328
BMC Health Serv Res. 2019 Oct 24;19(1):747
pubmed: 31651307
N Engl J Med. 2017 Mar 30;376(13):1256-1267
pubmed: 28355514
Int J Epidemiol. 2012 Aug;41(4):977-87
pubmed: 22933646